2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2643

Grey Matter Decrease in Fibromyalgia Is Related to Pain Catastrophizing and Pain Sensitivity
Abstract Number: 122

Grey-Scale Ultrasonography with Power Doppler Technique: An Available Tool for the Assessment of Subclinical Joint Inflammatory Activity in Juvenile Idiopathic Arthritis
Abstract Number: 1244

Group Cycling in Rheumatoid Arthritis: Positive Effects On Aerobic Capacity and Blood Pressure
Abstract Number: 1355

Hand Bone Loss Is Arrested in Early Psoriatic Arthritis but Not in Rheumatoid Arthritis Following Anti-Rheumatic Treatment Assessed by Digital X-Ray Radiogrammetry
Abstract Number: 967

Haplotypes of GTP Cyclophydrolase Gene Polymorphisms Are Protective in the Susceptibility of Fibromyalgia Syndrome
Abstract Number: 1086

Has the Level of Disability At Time of TKR Changed Over the Past 10 Years?: Results From Two National Cohorts
Abstract Number: 2449

Head to Head Comparison of Subcutaneous Abatacept Versus Adalimumab in the Treatment of Rheumatoid Arthritis: Key Efficacy and Safety Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Abstract Number: 622

Headache in Systemic Lupus Erythematosus (SLE): Results From a Prospective, International, Inception Cohort Study
Abstract Number: 931

Health Care Utilization Among Medicaid Enrollees with Systemic Lupus Erythematosus Preceding the Development of End-Stage Renal Disease: Sociodemographic Variation
Abstract Number: 93

Health State Utilities in Systemic Sclerosis: Results From the UCLA Scleroderma Quality of Life Study
Abstract Number: 1394

Health Status Burden and Impact of Fatigue On Patient Functioning in SLE Patients From a Phase 1b Study
Abstract Number: 2427

Health-Related Quality of Life in Adolescents with Rheumatic Disease
Abstract Number: 1833

Healthcare Costs in Psoriatic Arthritis Patients Newly Initiated On a Biologic Disease-Modifying Anti-Rheumatic Drug or Methotrexate
Abstract Number: 1502

Hedgehog Signaling in Murine Chronic Sclerodermatous Graft-Versus-Host Disease
Abstract Number: 1250

Heightened Aortic Wall Inflammation in Patients with Rheumatoid Arthritis Versus Patients with Established Coronary Artery Disease without Autoimmune Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].